BioAtla, Inc., also known as BCAB, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel, highly specific and selective therapeutics for the treatment of various forms of cancer. The company employs a unique technology platform known as Conditionally Active Biologics (CAB), which enables the production of therapeutic proteins and antibodies that are designed to be activated only in specific microenvironments within the body.
The company’s lead program, CAB-ROR2-ADC, is an antibody-drug conjugate that targets ROR2, a cell surface receptor that is overexpressed in a range of solid tumors. This novel therapy is designed to deliver a potent cytotoxic agent directly to cancer cells, sparing healthy tissue from the harmful effects of traditional chemotherapy.
BioAtla's robust pipeline also includes several other therapeutic candidates that are currently in various stages of development. These include a bispecific antibody candidate for the treatment of non-small cell lung cancer and other solid tumors, and a CAR T-cell therapy for hematologic malignancies.
Founded in 2007, the company is headquartered in San Diego, California, but operates globally with additional facilities in Beijing, China. BioAtla's objective is to leverage the proprietary CAB platform to develop therapeutics that have the potential to improve therapeutic efficacy while minimizing the side effects associated with traditional cancer treatments.
In December 2020, BioAtla completed an initial public offering and began trading on the Nasdaq Global Market under the ticker symbol BCAB. Despite being relatively newly listed, the company has attracted attention due to its innovative approach to cancer therapy, which exemplifies the ongoing shift in oncology towards highly specific, targeted therapies.
In conclusion, BioAtla, Inc. (BCAB) is a pioneering player in the field of biopharmaceuticals with its unique cancer-targeting technology. With a number of promising candidates in its pipeline, the company is set to play a significant role in shaping the future of cancer treatment.